EACTS Daily News  Tuesday 30 October 2012  33

Thoracic: Focus Sesion  14:15–15:45  Room 133/134

Continued from page 32

09:40

Is there a role for surgery in acute pulmonary embolism? Wolfgang Harringer  Klinikum Braunschweig, Braunschweig, Germany

A

lthough Trendelenburg first described surgical embolectomy for acute pulmonary embolism back in 1908 the procedure has only found its break through over the last decades. This becomes most obvious in the fact that guidelines only recommend pulmonary embolectomy in case of serious hemodynamic instability and high risk, failure or contraindication to lysis. The low acceptance of the Trendelenburg procedure is mainly attributed to the very high mortality that initially even reached 100%. As lysis for acute coronary syndroms has lost its merits over the last decade through the improvement of catheter techniques that introduced the possibility of a more goal directed

treatment of culprit lesions the evolution of surgical know how could likewise change our treatment perspectives for acute pulmonary embolism. Hence giving a greater role for surgery in hemodynamically stable patients with right ventricular dysfunction in whom lysis remains the golden standard. This view seems justified by the radical drop of mortality in association with surgical treatment, mortality rates as low as 6.4% being described nowadays. Crucial for achieving such excellent results are a fast and accurate diagnosis in addition to a rapid decision making for which an interdisciplinary team approach between cardiologists and surgeons appears mandatory. Extracorporeal membrane oxygenators could play an important role in this setup offering an excellent bridging technique between stabilization (oxygenation and relief of right ventricular dys-

function) and definite surgical treatment. Progresses made in this field have made these devices readily available, easy to apply and reduced the associated morbidity to acceptable levels. Miniaturization and biocompatible coating have resulted in a reduction of foreign surface contact, bleeding complications and inflammatory response. Minimized perfusion circuits which have followed a similar philosophy may also contribute to the success of surgery especially considering a reduction of inflammatory response that may play an underestimated role in the pathogenesis that follows pulmonary embolism. In conclusion a rapid diagnosis and interdisciplinary decision making for best treatment strategy will prompt a more aggressive surgical treatment even in hemodynamically stable patients with right ventricular dysfunction. The lack of scien-

How to do a mini aortic valve replacement P. Sardari Nia (Breda) 10:10 How to do a mini-maze W.-J. Van Boven (Amsterdam) 10:30 Break 11:00

How to do a thoracic endovascular aortic repair M. Czerny (Berne) 11:20 How to do an endovascular coronary artery bypass N. Bonaros, (Innsbruck) 11:40 How to do video-assisted thoracoscopic epicardial lead placement B. Van Putte (Breda) 12:00 Ends

Advanced Techniques 09:00 Lateral Thinking Room 111 09:00 Wolfgang Harringer 

tific evidence in terms of prospective randomized trials remains the main obstacle for a more liberal choice for surgery. This barrier will only be overcome through a heart team approach.

09:09 09:18 09:27 09:36 09:45

Cardiac: Abstract  14:15–15:45  Room 114

09:54

Nitinol flexigrip sternal closure system and standard sternal steel wiring: Insight from a matched comparative analysis Jonida Bejko, Tomaso Bottio, Vincenzo Tarzia, Marco De Franceschi, Roberto Bianco, Michele Gallo, Massimo Castoro, Gino Gerosa  Institute of Cardiovascular Surgery. Padova, Italy

S

ternal wound instability (SWI) and/or infection are still active and life-threatening complications in cardiac surgery. The pathogenesis is not yet clearly defined, and many authors identified several factors, patient or surgeon related, as potential causes. The Flexigrip (Praesidia, Bologna – Italy) is a sternal closure system, composed of thermoreactive alloy of Nichel and Titanium with a memory effect, which acts as a brace holding together the sternal osteotomy. We sought to assess the efficiency of two different sternal closure techniques in preventing

Tomaso Bottio

sternal wound instability in high risk patients. Between January-09 and February-12, 2,068 consecutive cardiac-patients have been prospectively collected in our database. Based on the observation that in the vast majority of cases of sternal wound infections some degree of sternal instability is always present, we com-

pared the results observed in two population of matched patients in whom two different sternal wiring techniques were adopted, using the same triplelayer suture for fascia, subcutaneous tissue and skin. The 561 patients in whom the thermoreactive-Nitiliumclips (Flexigrip) have been used (Group A), were matched 1:1

with 561 patients who received a standard parasternal wiring technique (Group B) on 10 available risk factors known to affect sternal wound healing (age, age > 75-year, gender, diabetes-mellitus, cardiac-procedure, obesity, re-intervention, cross-clamp, and total operative times). The study was completed with a cost analysis.

The two groups were well matched, although different for bilateral internal thoracic harvesting, chronic obstructive pulmonary disease, renal insufficiency, and congestive heart failure which were significantly more frequent in Group A. At 30-days of follow-up, the association wound-complication and sternal instability was significantly less frequent in Group A versus Group B (0.2% versus 1.6%) (p=0.04). Overall incidence of sternal wound complication was lower in Group A (2% versus 3.5%) (p=0.28). In presence of wound infection, a sternal wound instability was never observed in Group A (p=0.06). Overall costs were €8,701,854 and €9,243,702 in Group A and B, respectively, thus Flexigrip closure technique offered a €541,848 cost saving. Flexigrip used in high risk patients showed a lower incidence of sternal wound instability with no need of sternal re-wiring in any case, even in presence of wound infection. Flexigrip proved to be also cost-effective.

10:03

Why are we here today? Introduction, background and goals of this session J. Seeburger (Leipzig) How simple ideas can influence our practice O. Alfieri (Milan) What do patients want and need? M. Misfeld (Leipzig) Societies (EACTS, AATS, STS, ESC...): Lobby for whom? V. Falk (Zürich) A randomized trial in the NEJM: the holy grail of marketing? M. Mack (Dallas) The next generation of cardiac surgeons: where to go? T. Noack (Leipzig) Doctor and business man: conflict of interest? J. Pomar (Barcelona) Technology transfer in cardiac medicine: money, ego, career? E. Schwammenthal (Tel Aviv)

10:12 Break 10:30 10:39

10:48 10:57 11:06 11:15 11:51

How to make the most of your ideas and your future self F. Litvack (Los Angeles) Is cardiac medicine worth the effort? Insights from economy M. Rosenmoller, IESE Business School (Barcelona) Will I make money investing in cardiac surgery? J Mack (Mounds View) On the road again: why give up cardiac surgery? M. Studer (Dübendorf) Think Tank cardiac surgery S. Haider (Erlangen) Discussion Closing Remarks V. Falk (Zürich)

Advanced Techniques 09:00 The mitral and tricuspid valves: repair techniques Room 113

Moderator: J. R. Pepper, London; P. van de Woestijne, Rotterdam 09:00

Pathophysiology of functional mitral and tricuspid regurgitation K. M. J. Chan (London) 09:25 Assessment of functional mitral and tricuspid regurgitation L Pierard (Liege) 09:50 Natural history and medical treatment of functional mitral and tricuspid regurgitation T. McDonagh (London) 10:15 Break 10:45

Cardiac: Focus Session  16:15–17:45  Room 120/121

11:10

Antibiotic prophylaxis for infective endocarditis: Time for a definitive answer? Bernard Prendergast  John Radcliffe Hospital, Oxford, UK

I

nfective endocarditis is an elusive and dangerous condition which challenges all those involved in its management. Cardiologists and cardiac surgeons, who encounter patients with severe complications of the disease destined for complex cardiac surgery or post mortem, fear its consequences and have maintained the dogma of prevention by means of antibiotic prophylaxis prior to invasive procedures. The evidence to support this stance is limited and revised European and US guidelines in recent years have resulted in a major shift of emphasis in this contentious area. Moreover, guidance from the UK National Institute for Health and Clinical Excellence (NICE) published in 2008 abolished this practice completely with no adverse consequences to date. Is it now time for further evaluation and a definitive randomised controlled trial? Changing epidemiology and evidence to date The clinical profile of IE is changing with increasing frequency of Staphylo-

coccus aureus and falling incidence of IE secondary to oral streptococci. IE often arises in patients without previously documented cardiac disease when the question of prophylaxis is irrelevant. Even if antibiotic prophylaxis is applied appropriately, the evidence to support its efficacy is limited to casecontrol analyses. Even if these studies are negative, they also fail to demonstrate that antibiotic prophylaxis of IE is ineffective. They do, however, suggest that a huge number of prophylaxis doses are necessary to prevent a very low number of IE cases and that the risk of developing IE after an unprotected at-risk dental procedure is extremely low. Whilst a randomised placebo controlled trial to address the benefits of antibiotic prophylaxis in preventing IE is desirable, such a study would be a massive undertaking, requiring large numbers of patients in each arm to provide adequate statistical power. The heterogeneity of the underlying cardiac conditions and invasive procedures would make stratification extremely difficult but a trial focussing on the highest risk groups (eg. those with a prosthetic valve) could

be achieved with sufficient statistical power to allow extrapolation to other lower risk cohorts. The UK is the only nation where such a trial could be ethically performed and preliminary plans are currently being conceived. Guidelines and philosophy The original “treat all” philosophy was based upon an understandable fear of infective endocarditis and its complications. However, the number needed to treat for effective prevention is exceedingly high and routine antibiotic administration is not risk free. Anaphylaxis to β-lactam antibiotics occurs in 15-40 per 100,000 uses and there are legitimate concerns regarding community-derived antibiotic resistance. Moreover, the cost-effectiveness of routine antibiotic prophylaxis is questionable. The European and US guidelines advocate the “number needed to treat” or “bang for your buck” philosophy, restricting use of antibiotic prophylaxis to patients at the highest risk of IE undergoing the highest risk procedures. Antibiotic prophylaxis is no longer recommended for patients with native valve disease nor for any gastrointestinal or genitourinary procedures.

Going one step further, the UK NICE guidelines espouse the “proof of principle” philosophy and recommended an end to the practice of antibiotic prophylaxis altogether. To date, this seemingly radical recommendation has not been accompanied by the predicted surge in the incidence or mortality of infective endocarditis in the UK, though continued prescribing to high risk groups seems likely may be a confounding source of positive reassurance. Let’s test the hypothesis... Notwithstanding the current paucity of evidence, it is clear that the efficiency of current practice is restricted due to the exorbitant number needed to treat to prevent a single case of IE, with potential for overall harm. A shift of the fundamental question from “Who is at risk?” to “Who might benefit?” therefore seems appropriate. National or international registries may provide useful information and previous ethical concerns obstructing the required randomised controlled trial have now been removed. Whether, there will be sufficient political imperative and enthusiasm to undertake such a major endeavour remains to be seen.

11:35 11:35 11.55 12:15

Surgical treatment of functional mitral regurgitation R. Dion (Genk) Surgical treatment of functional tricuspid regurgitation G. Dreyfus (Monte-Carlo) Newer approaches: when do percutaneous techniques offer a solution? F. Maisano (Milan) An alternative surgical treatment to tricuspid regurgitation J-P Couetil (Paris) Newer approaches: when do percutaneous techniques offer a solution F. Maisano (Milan) Conclusion

This session is supported by an unrestricted educational grant from Edwards Lifesciences

Advanced Techniques 09:00 New surgical treatment concepts for heart failure Rooms 131/132 Organized by the the Roland Hetzer International Cardiothoracic Vascular Surgery Society (RHICS)

Moderators: F. Beyersdorf, Freiburg; R. Hetzer (Berlin) 09:00 09:20 09:40 10:00 10:20 10:40

Organ-conserving surgery F. Beyersdorf (Freiburg) Cardiac resynchronization therapy C. Butter (Berlin) Revascularization surgery J. Ennker (Lahr) State of the art in heart transplantation R. Hetzer (Berlin) Role of left ventricular assist device M. Morshuis (Bad Oeynhausen) Role of right ventricular assist device T. Krabatsch (Berlin)

Continued on page 34

34  Tuesday 30 October 2012  EACTS Daily News

Continued from page 33

11:00 11:20 11:40 12:00 12:20 12:40

Role of biventricular assist device E. Potapov (Berlin) Total artificial heart M. Loebe (Houston) Paediatric ventricular assist device V. Alexi-Meskishvili (Berlin) End-stage congenital heart disease E. M. Delmo Walter (Berlin) Regenerative medicine C. Stamm (Berlin) Panel discussion R. Hetzer (Berlin), F. Beyersdorf (Freiburg),   G. Schuler (Leipzig), F. Musumeci (Rome),   C. Mestres (Barcelona), H. Schafers (Homburg/Saar)

Advanced Techniques 08:30 Controversies and catastrophies in adult cardiac surgery Room 115

Organiser: M. Shrestha, Hannover Moderators: R. Haaverstad, Bergen; G. Rajbhandary, Nepal; A. Martens, Hannover 08:30 08:40

08:50 09:00

09:20 09:40

10:00

Introduction M. Shrestha (Hannover) Completion coronary angiogram after coronary artery bypass grafting: is it necessary? J. Bauersachs (Hannover) Presentation of single-centre data F. Fleissner (Hannover) Tissue-engineered valves: all smoke without fire? G. Gerosa (Padua) View from industry J. McKenna, (United Kingdom) Aortic valve endocarditis: when to operate? C. Mestres (Barcelona) Aortic valve replacement in high-risk patients: classical aortic valve replacement through minithoracotomy is superior to transcatheter aortic valve implantation M. Glauber (Massa) Closure of circumflex artery during MIC mitral valve operation: is the danger real? V. Falk, Zürich

10:20 Coffee 10:40

Redo mitral valve replacement for reiterative desinsertion: what to do T. Folliguet (Nancy) 11:00 Aortic valve in acute aortic dissection type A: to repair or replace? C. Hagl (Munich) 11:20 Closing remarks M. Shrestha (Hannover

Advanced Techniques 09:00 Part I: Aortic valve repair for the nonexpert: a stepwise approach Rooms 133/134

Moderators: D. Pagano, Birmingham;   R. Sádaba, Pamplona

How to start an aortic valve repair programme J. Vojacek (Hradec Kralove) How to select a good candidate V. Delgado (Leiden) How to repair a tricuspid aortic valve E. Lansac (Paris) How to repair a bicuspid aortic valve G Mecozzi, (Enschede)

Wetlab Training Session 10:45 Part II: Wetlab: Valve-sparing aortic root replacement Rooms 120/121

Organiser: D. Pagano (Birmingham) Lead Convenors: M. Lewis, Brighton;   E. Lansac, Paris; M. Redmond, Dublin Learning objectives: At the end of this wetlab, the candidate will be able to: n describe the methods used to perform valve sparing root replacement n explain the reasons that one technique might be used in place of another n perform the techniques in a wetlab environment



Welcome M. Lewis Re-implantation techniques M. Redmond (Dublin) Re-modelling techniques including the Lansac Ring E. Lansac (Paris)

Wetlab session



Summary, feedback and close E. Lansac, M. Lewis

Limited to 40 participants Attendees at the wet lab should attend Part I: Aortic valve repair for the non-expert, a stepwise approach

Wetlab Training Session 09:00 Strategies to deal with mitral repair using Gore-tex chords Rooms 122/123

Organiser: D. Pagano (Birmingham) Lead Convenors: M. Lewis (Brighton) Faculty: P. Perier (Bad Neustadt/Saale),   W. C. Hargrove III, Philadelphia, S. Livesey (Southampton), M. Lewis, (Brighton) Continued on page 35

Complete EACTS Membership Applications for 2012 We are pleased to confirm that we have received 347 complete EACTS membership applications for 2012. These applications have been formally accepted by the General Assembly on Monday, 29 October. From now on, we are happy to receive new EACTS Membership Applications for the year 2013. Please, spread the word amongst your colleagues. EACTS Membership provides access to a network of knowledge and the opportunity to develop your own expertise and share this with fellow professionals. http://www.eacts.org/content/membership-application

EACTS Daily News  Tuesday 30 October 2012  35

Continued from page 34

Learning objectives: At the end of this wetlab, the candidate will be able to: n Describe the methods used to repair the mitral valve using Gore-tex neochords and a mitral ring n Explain the reasons why one technique might be used in place of another n Perform the techniques in a wetlab environment Programme (90 minutes per iteration)



Welcome: M. Lewis Anatomy of the mitral valve (Lecture, 10 minutes) W. C. Hargrove III Repair techniques (Lecture, 10 minutes) P. Perier, W. C. Hargrove III



Wetlab session (70 minutes)



Summary, feedback and close

M. Lewis

Limited to 40 participants

10:30 Session ends

Congenital Heart Disease Advanced Techniques in Cardiothoracic and Vascular Surgery Wetlab Training Session 09:00 Operative techniques – aortic valve repair and the MAZE procedure Rooms 129/130

Co-ordinator: W. Brawn, London Faculty: C. Brizard, Melbourne; V. Hraska, Sankt Augustin; S. Tsao, Chicago Learning objectives: n To understand the aortic valve repair procedures and the maze procedure pertaining to congenital heart malformations Programme: n Different techniques for aortic valve repair V. Hraska, Sankt Augustin; C. Brizard, Melbourne n Maze procedure: B Brawn (Birmingham) S. Tsao (Chicago); A. Coane (AtriCure) Target Audience: n Surgeons performing congenital heart surgery in patients from infancy through to adulthood Limited to 40 participants

Advanced Techniques 09:00 Part I: Aortic valve repair for the nonexpert: a stepwise approach Rooms 118/119 08:30

Interesting cases and small series on orphan aortic diseases and pathological mechanisms Moderators: M. Czerny, Berne; A. Moritz, Frankfurt

08:30

A touristic danger in the Alps: acute type A aortic dissection in alpine skiers N. Fischler, J. Holfeld, W. Schobersberger, A. Strasak, M. Grimm (Austria) Discussant: R. Haaverstad (Bergen)

08:45

Usefulness of coil treatment for type I endoleak in thoracic endovascular aortic repair using a fenestrated stent graft K. Hanzawa, T. Okamoto, O. Namura, M. Tsuchida, Y. Yokoi (Japan) Discussant: B. Zipfel (Berlin)

09:00

Arteria luzoria as a risk factor for spinal cord ischaemia L. Bockeria, V. Arakelyan, N. Gidaspov (Russian Federation) Discussant: D. Kotelis (Heidelberg)

09:15

Endovascular stent graft repair of the ascending aorta: assessment of a specific novel stent graft design in phantom, cadaver and clinical application M. Funovics, M. Popovic, G. Erman, J. Lammer (Austria) Discussant: C. Antona (Milan)

09:30

Acute retrograde type A aortic dissection after complete debranching of the supra-aortic branches and stent grafting of the transverse aortic arch M. Luehr, C. Etz, L. Lehmkuhl, F. Mohr, M. Borger (Germany) Discussant: L. Di Marco (Bologna)

09:45 Break 10:00 Clinical tips and tricks in vascular access for open and endovascular therapy

Moderators: E. Weigang, Mainz;   M. Grabenwöger, Vienna 10:00 10:15 10:30 10:45 11:00 11:15 11:30 11:45

Apical access E. Weigang (Mainz) Ascending aortic access J. Bavaria (Philadelphia) Carotid access P. Urbanski (Bad Neustadt) Subclavian access M. Grabenwöger (Vienna) Infrarenal access M. Grimm (Innsbruck) Retroperitoneal access M. Czerny (Berne) Femoral access T. Friess (Mainz) Percutaneous access using closure devices M. Funovics (Vienna)

12:00 Session ends

36  Tuesday 30 October 2012  EACTS Daily News

Floor plan

Training Village 134

Catering

132

100

101

102

103

110

111

112

96

97

98

99

107

108

109

92

93

94

95

88

89

90

91

Catering

72

73

74

67

68

69

70

Catering

9

106

81 71

Catering

80

116

82 87

8

129

130

131

126

127

128

10 11 12

7 13 6

63

64

65

66

5

59

60

61

62

79

115

124

105

86

123

14 125

15

4 16 78

55 51

121

114

53

120

17 122

18 19

47

118

43

45

85

77

104

113

117

119

3 2 31

1

32

33

34

35

38

39

36

37

40

41

20

42

21

30

29

ENTRANCE

28

27

26

25

24

23

ENTRANCE

27

A&E Medical Corporation

117

Delacroix-Chevalier

51

Labcor Laboratorios Ltda

87

Siemens AG

39

AATS

98–99 Dendrite Clinical Systems

66

Lepu Medical Technology (Beijing) Co Ltd

91

Smartcanula LLC

115

Abbott Vascular International BVBA

123

De Puy Synthes

110–111 LSI Solutions

85

Sorin

17

Andocor

35

EACTS

102

Mani Inc

106

St Jude Medical

28–29 Asanus Medizintechnik GmbH

104

Edwards Lifesciences

86

Maquet Cardiopulmonary AG

96

Starch Medical Inc

45

AtriCure Inc

107–109 Estech Inc

15

Master Surgery Systems AS

36

STS

114

B Braun Surgical S.A.

120

Ethicon – Johnson & Johnson

74

MDD Medical Device Development GmbH

73

Sunshine Heart

13–14 Baxter Healthcare SA

112

Euromacs

3

Medafor Inc

41

Symetis SA

82

Berlin Heart GmbH

78

Eurosets SRL

65

Medex Research Ltd

126–127 SynCardia Systems Inc

16

BioCer Entwicklungs-GmbH

118

Fehling Instruments GmbH & Co KG

116

Medistim ASA

77

12

Biomet Microfixation

34

Geister Medizintechnik GmbH

40

Medos Medizintechnik AG

Terumo Europe Cardiovascular Systems (TECVS) 

92–93 BioVentrix Inc

119

Genesee BioMedical Inc

105

Medtronic International Trading SÁRL

103

The Society for Heart Valve Disease

129

Bolton Medical

69

Geomed®Medizin-Technik GmbH & Co. KG

88–89 MiCardia Corporation

113

Thoratec Corporation

80

BracePlus/Slimstones BV

23

Gunze Limited

9

Micromed CV Inc

55

Tianjin Plastics Research Institute

NeoChord Inc

132

TransMedics Inc

Neomend Inc

19

Transonic Systems Europe

On-X Life Technologies INC™

130

ValveXchange

70 125 10

Cardia Innovation AB CardiaMed BV Cardio Medical GmbH

68 72 26

Hamamatsu Photonics Heart and Health Foundation Heart Hugger / General Cardiac Technology

67 131 42

53

CareFusion

32

HeartWare Inc

30

Oxford University Press

20–21 Wexler Surgical Inc

90

CASMED

11

Integra

134

PCR

1–2

Wisepress Online Bookshop

97

WL Gore & Associates GmbH

4–8

100–101 Intuitive Surgical Sarl

124

Peters Surgical

59–61 Cook Medical

38

ISMICS

62

Praesidia Srl

31

CorMatrix Cardiovascular Inc

81

Jarvik Heart Inc

128

Qualiteam SRL

122

Coroneo Inc

63–64 Jena Valve Technology GmbH

25

Redax SRL

24

Correx Inc

121

18

Rumex International Co

79

Cryolife Europa Ltd

43–47 Karl Storz GmbH & Co KG

71

Sanofi Biosurgery

37

CTSNET

94–95 KLS Martin Group

33

Scanlan International Inc

CircuLite GmbH

JOTEC GmbH

38  Tuesday 30 October 2012  EACTS Daily News

EACTS events Advanced Module: Heart Failure – State of the Art and Future Perspectives 12–17 November 2012 – 2 days of wetlabs EACTS House, Windsor, UK Course Directors: G Gerosa, Padua; M Morshuis, Bad Oeynhausen The course will be organised in 10 modules: 1 Epidemiology/Pathology; 2 Diagnostic/Imaging; 3 and 4 Optimal Medical Therapy/IC ; Resynchronization; 5 Cardiac Surgery (Indications, Techniques, Results); 6 Heart Transplant (Indications, Techniques, Results) 7 VADs/TAH (Indications, Techniques, Results); 8 HTx/VADs in Paediatric Population; 9 Stem Cells Regenerative Medicine; 10 Wet Labs/Live in a Box/Group Projects Course Objectives: To update knowledge of theoretical and technical issues of surgery for heart failure.

Leadership and Management Development for Cardiovascular and Thoracic Surgeons 20– 23 November 2012 EACTS House, Windsor, UK Course Directors – J L Pomar, Barcelona The Leadership and Management Development

Course is an intensive five-day programme in two parts with a three day initial training session followed by a further two days of training scheduled six months later. The course will utilise a mix of pre and post programme activities and each delegate will be tasked with exploring leadership best practise during the break between the two parts of the programme. Course Objectives: Improve, enhance and maximise your leadership attributes

Thoracic Surgery Part II 3rd – 7th December 2012 EACTS House, Windsor, UK Course Directors – P Rajesh, Birmingham n The course programme includes: n Tracheal Surgery n Tracheobronchial injuries n Tracheal-main bronchus obstruction; n Esophagus Cancer – Staging, preoperative; n Oesophageal cancer; n Thoracoscopic technique; n Mesothelioma treatments; n Metastatic disease; n Chest wall reconstruction; n Case presentations.

Course Objectives: To gain more insight and up-to-date knowledge on different aspects of thoracic surgery related to tracheal, pleural, mediastinal and oesophageal disease.

Chest Wall Diseases 28–30 November 2012 22 – 23, 2012, under the custody of EACTS, with the participation of 35 invited faculty from around the world. hest Wall Interest Group Now we want to reach a broader (CWIG) is a group belonging spectrum of residents, specialists and to the EACTS Thoracic Domain. It was founded during The Sec- academicians, thus we are organizing a workshop on “Chest Wall Disond International Nuss Procedure eases” in Windsor, UK, at EACTS Workshop held in Istanbul in June House, 28-30 November 2012. 2009. The main subjects are Congenital We have set out to establish a Chest Wall Deformities, Chest Wall channel of communication across Resection and Reconstruction, Thodifferent continents with a view to racic Outlet Syndrome and Sternal allow the exchange of knowledge Dehiscence. among those experienced practiThe Learning Objectives are; tioners who are studying, developing and innovating methods to treat Learning the indications, techniques and follow-up of minimally invachest wall diseases. In June 2010, sive and open surgery in pectus dewe got together again in Izmir, for formities; Learning the alternative The Third International Workshop on the Minimally Invasive Repair of treatments –surgical and nonsurgcal- for pectus deformities; LearnPectus Deformities under the custody of EACTS. The Workshop was ing chest wall resection and reconstruction techniques in chest wall a great success and we had the chance to discuss the future projec- diseases; Learning the surgical techniques in thoracic outlet syndrome tions of the CWIG. and Learning the treatment options Our next important meeting in –surgical and nonsurgical- in sternal the calendar was The Fourth Interdehiscence. national Chest Wall Interest Group The Target Audience is; Thoracic Workshop on Chest Wall Diseases Surgery Residents, Specialists and the which was held in Istanbul on June M Yuksel  Course Director, Istanbul; EACTS House, Windsor, UK

C

Academicians working in the field of Thoracic Surgery. We very much look forward to welcoming you to Windsor. To register for this course please visit: www.eacts.org/academy/specialistcourses/ chest-wall-diseases.aspx Regards, Prof. Mustafa Yuksel, MD

Introducing the Future of Transapical TAVI- the Medtronic Engager System * S

ince our entrance into the TAVI market, Medtronic has always been committed to providing multiple TAVI platforms. Heart teams need options to best treat their patients. By offering multiple valve platforms and access route options (transapical, transfemoral, direct aortic, and subclavian), Medtronic can help your team achieve the best outcome for each patient. Fulfilling this vision, the interim results from the Medtronic Engager European Pivotal Trial were presented yesterday during the Late Breaking Abstract Session. The early clinical experience is positive and demonstrates that the Engager System successfully puts you in control for precise positioning, tight annular sealing, and true anatomic alignment.

conforms to the native anatomy, Engager further seals the annulus by capturing the native leaflets between the control arms and the frame. An independent echo core lab found no PVL greater than trace at 30 days during the Pivotal Trial.

valve, securing the valve throughout deployment. With tactile control, deployment is simple and repeatableduring the Pivotal Trial, 100% devices were implanted in the correct anatomic position and there were no embolizations, second valves implanted, or annular ruptures.

Precise Positioning Engager’s unique control arms provide tactile feedback as they are PVL Minimized placed into the sinuses of the native While the self-expanding frame

True Anatomic Alignment Transcatheter valves must recreate hemodynamic function in every patient regardless of aortic shape or size. The Engager valve is designed to align with and conform to the native anatomy. Fixation of the native leaflets and true commissure-to-commissure alignment provide clearance for the coronary ostia while supra-annular valve position minimizes frame deformation at the leaflets to optimize coaptation in noncircular anatomy. Please join us today for the Medtronic TAVI Symposium (Room 113 12:45-14:00) to learn more about the future of TAVI, including a

live-case with the Medtronic Engager We look forward to sharing the Transapical TAVI System and an future with you. introduction to the CoreValve InVia** surgical access delivery system. *CE submitted. **Non-CE marked

EACTS Daily News Publisher Dendrite Clinical Systems Editor in Chief Pieter Kappetein Managing Editor Owen Haskins [email protected]

Design and layout Peter Williams [email protected] Managing Director Peter K H Walton [email protected]

Head Office The Hub Station Road Henley-on-Thames, RG9 1AY, United Kingdom Tel +44 (0) 1491 411 288 Fax +44 (0) 1491 411 399 Website www.e-dendrite.com

Copyright 2012 ©: Dendrite Clinical Systems and the European Association for Cardio-Thoracic Surgery. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, transmitted in any form or by any other means, electronic, mechanical, photocopying, recording or otherwise without prior permission in writing of the editor.